首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Development of piperazine-based hydroxamic acid inhibitors against falcilysin,an essential malarial protease
Authors:Jeffrey P Chance  Hannah Fejzic  Obiel Hernandez  Eva S Istvan  Armann Andaya  Nikolay Maslov  Ruby Aispuro  Teodulo Crisanto  Huyen Nguyen  Brian Vidal  Whitney Serrano  Bradley Kuwahara  Corey Pugne Andanado  Daniel E Goldberg  Jeremy P Mallari
Institution:1. Department of Chemistry and Biochemistry, California State University, San Bernardino, USA;2. Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, USA;3. Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, USA;4. Campus Mass Spectrometry Facilities, University of California, Davis, USA
Abstract:The human parasite Plasmodium falciparum kills an estimated 445,000 people a year, with the most fatalities occurring in African children. Previous studies identified falcilysin (FLN) as a malarial metalloprotease essential for parasite development in the human host. Despite its essentiality, the biological roles of this protease are not well understood. Here we describe the optimization of a piperazine-based hydroxamic acid scaffold to develop the first reported inhibitors of FLN. Inhibitors were tested against cultured parasites, and parasiticidal activity correlated with potency against FLN. This suggests these compounds kill P. falciparum by blocking FLN, and that FLN is a druggable target. These compounds represent an important step towards validating FLN as a therapeutic target and towards the development of chemical tools to investigate the function of this protease.
Keywords:RBC  Red blood cell  IPTG  FLN  Falcilysin  PMSF  Phenylmethylsulfonyl fluoride  TEA  Triethylamine  ER  Endoplasmic reticulum  DMAP  4-Dimethylaminopyridine  Falcilysin  Malaria  Protease inhibitors  Metalloprotease  Hydroxamic acid
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号